Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18529410 | 1.00 | ALDH1A1 (0.49) | ALDH1A1CYP3A4ALOX15TDP1KDM4E | |
| SCHEMBL2131065 | 1.00 | ALDH1A1 (0.49) | ALDH1A1CYP3A4ALOX15TDP1KDM4E | |
| SCHEMBL11449382 | 1.00 | ALDH1A1 (0.49) | ALDH1A1CYP3A4ALOX15TDP1KDM4E | |
| SCHEMBL20479049 | 1.00 | ALDH1A1 (0.49) | ALDH1A1CYP3A4ALOX15TDP1KDM4E | |
| SCHEMBL454167 | 1.00 | ALDH1A1 (0.49) | ALDH1A1CYP3A4ALOX15TDP1KDM4E | |
| SCHEMBL18529411 | 1.00 | ALDH1A1 (0.49) | ALDH1A1CYP3A4ALOX15TDP1KDM4E | |
| SCHEMBL454166 | 1.00 | ALDH1A1 (0.49) | ALDH1A1CYP3A4ALOX15TDP1KDM4E | |
| SCHEMBL10995198 | 0.94 | ALDH1A1 (0.45) | ALDH1A1CYP3A4ALOX15TDP1KDM4E | |
| SCHEMBL580300 | 0.83 | ALDH1A1 (0.38) | ALDH1A1CYP3A4ALOX15TDP1KDM4E | |
| SCHEMBL580302 | 0.83 | ALDH1A1 (0.38) | ALDH1A1CYP3A4ALOX15TDP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4514477-A1 | FRAGRANCE COMPOSITIONS HAVING LONG-LASTING TRAIL PERFORMANCE | Firmenich SA (CH) | 2025-03-05 | — | — | EP | claimed |
| EP-4319716-A1 | COMPOSITIONS TO LIMIT, REDUCE OR ELIMINATE MALODOURS ASSOCIATED WITH PLASTIC MATERIALS | Firmenich SA (CH) | 2024-02-14 | — | — | EP | claimed |
| US-20230404887-A1 | COMPOSITIONS TO LIMIT OR ELIMINATE THE PERCEPTION OF SWEAT MALODOR | FIRMENICH SA (CH) | 2023-12-21 | — | — | US | claimed |
| EP-4161476-A1 | COMPOSITIONS TO LIMIT OR ELIMINATE THE PERCEPTION OF SWEAT MALODOR | Firmenich SA (CH) | 2023-04-12 | — | — | EP | claimed |
| WO-2022253712-A1 | COMPOSITIONS TO LIMIT, REDUCE OR ELIMINATE MALODOURS ASSOCIATED WITH PLASTIC MATERIALS | FIRMENICH SA (CH) | 2022-12-08 | — | — | WO | claimed |
| WO-2022084548-A1 | COMPOSITIONS TO LIMIT OR ELIMINATE THE PERCEPTION OF SWEAT MALODOR | FIRMENICH SA (CH) | 2022-04-28 | — | — | WO | claimed |
| EP-4713129-A1 | ORGANOSILICON-BASED MICROCAPSULES | Firmenich SA (CH) | 2026-03-25 | — | — | EP | disclosed |
| EP-4661689-A1 | MICROPARTICLES CONTAINING ALGAL PROTEINS AND USES THEREOF | Firmenich SA (CH) | 2025-12-17 | — | — | EP | disclosed |
| EP-4651987-A1 | MICROCAPSULES FROM POLYLACTONE BASED PREPOLYMER | Firmenich SA (CH) | 2025-11-26 | — | — | EP | disclosed |
| EP-4633791-A1 | PROTEIN-BASED MICROCAPSULES | Firmenich SA (CH) | 2025-10-22 | — | — | EP | disclosed |
| EP-4604909-A1 | LIPID-BASED MICROCAPSULES | Firmenich SA (CH) | 2025-08-27 | — | — | EP | disclosed |
| EP-4604741-A1 | WAX-BASED MICROCAPSULES | Firmenich SA (CH) | 2025-08-27 | — | — | EP | disclosed |
| EP-4551185-A1 | FRAGRANCE COMPOSITIONS CONTAINING 2,3-BUTANEDIOL AND/OR 1,3-BUTANEDIOL | Firmenich SA (CH) | 2025-05-14 | — | — | EP | disclosed |
| WO-2022207526-A1 | FUNCTIONALIZED CHITOSAN PREPARATION | FIRMENICH SA (CH) | 2022-10-06 | — | — | WO | disclosed |
| WO-2022207525-A1 | COATED CORE-SHELL MICROCAPSULES | FIRMENICH SA (CH) | 2022-10-06 | — | — | WO | disclosed |
| WO-2022084548-A1 | COMPOSITIONS TO LIMIT OR ELIMINATE THE PERCEPTION OF SWEAT MALODOR | FIRMENICH SA (CH) | 2022-04-28 | — | — | WO | disclosed |
| US-10150730-B2 | Process for preparing α-damascone | BASF SE (DE) | 2018-12-11 | — | — | US | disclosed |
| US-20180244613-A1 | PROCESS FOR PREPARING ALPHA-DAMASCONE | BASF SE (DE) | 2018-08-30 | — | — | US | disclosed |
| EP-3337781-A1 | PROCESS FOR PREPARING ALPHA-DAMASCONE | BASF SE (DE) | 2018-06-27 | — | — | EP | disclosed |
| WO-2017029313-A1 | PROCESS FOR PREPARING ALPHA-DAMASCONE | BASF SE (DE) | 2017-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180244613-A1 | PROCESS FOR PREPARING ALPHA-DAMASCONE | ADH1C, TALDO1, NOS1 | ALDH1A1 15/4885CYP3A4 534/4885ALOX15 237/4885 |
| US-10150730-B2 | Process for preparing α-damascone | NOS1, ADH1C, ADH1A | ALDH1A1 8/4885CYP3A4 507/4885ALOX15 196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.